OLIMEL 7.6% 7.44 G
L-ARGININE : 7.44 G L-TYROSINE : 0.2 G L-PROLINE : 4.53 G L-LEUCINE : 5.26 G TRYPTOPHAN : 1.26 G LYSINE (L-LYSINE ACETATE) : 5.97 G GLUTAMIC ACID : 3.79 G DEXTROSE : 80.67 G SOYBEAN OIL : 7 G L-ISOLEUCINE : 3.79 G GLYCINE : 5.26 G METHIONINE : 3.79 G HISTIDINE : 4.53 G SERINE : 3 G L-THREONINE : 3.79 G L-PHENYLALANINE : 5.26 G L-ASPARTIC ACID : 2.2 G L-VALINE : 4.86 G ALANINE : 10.99 G OLIVE OIL : 28 G · DIN 02477947 · BAXTER CORPORATION
Health Canada status: MARKETED
What is OLIMEL 7.6%?
OLIMEL 7.6% 7.44 G contains L-ARGININE : 7.44 G L-TYROSINE : 0.2 G L-PROLINE : 4.53 G L-LEUCINE : 5.26 G TRYPTOPHAN : 1.26 G LYSINE (L-LYSINE ACETATE) : 5.97 G GLUTAMIC ACID : 3.79 G DEXTROSE : 80.67 G SOYBEAN OIL : 7 G L-ISOLEUCINE : 3.79 G GLYCINE : 5.26 G METHIONINE : 3.79 G HISTIDINE : 4.53 G SERINE : 3 G L-THREONINE : 3.79 G L-PHENYLALANINE : 5.26 G L-ASPARTIC ACID : 2.2 G L-VALINE : 4.86 G ALANINE : 10.99 G OLIVE OIL : 28 G. It is listed in the Health Canada Drug Product Database under DIN 02477947, held by BAXTER CORPORATION, supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 26-Jul-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OLIMEL 7.6% used for?
OLIMEL (amino acids, dextrose, lipids) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02477947 |
|---|---|
| Brand name | OLIMEL 7.6% |
| Generic / active ingredient | L-ARGININE : 7.44 G L-TYROSINE : 0.2 G L-PROLINE : 4.53 G L-LEUCINE : 5.26 G TRYPTOPHAN : 1.26 G LYSINE (L-LYSINE ACETATE) : 5.97 G GLUTAMIC ACID : 3.79 G DEXTROSE : 80.67 G SOYBEAN OIL : 7 G L-ISOLEUCINE : 3.79 G GLYCINE : 5.26 G METHIONINE : 3.79 G HISTIDINE : 4.53 G SERINE : 3 G L-THREONINE : 3.79 G L-PHENYLALANINE : 5.26 G L-ASPARTIC ACID : 2.2 G L-VALINE : 4.86 G ALANINE : 10.99 G OLIVE OIL : 28 G |
| Manufacturer | BAXTER CORPORATION |
| Strength | 7.44 G |
| Dosage form | EMULSION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA10 COMBINATIONS |
| AHFS class | 40:20.00 ; 40:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Jul-2021 |
| Original market date | 2018-10-25 00:00:00 |
How is it stored and handled?
null
How is it supplied?
650 mL bag: 1 carton with 10 bags 1000 mL bag: 1 carton with 6 bags 1500 mL bag: 1 carton with 4 bags 2000 mL bag: 1 carton with 4 bags
What can be used instead?
Other Canadian products sharing ATC code B05BA10 COMBINATIONS. 22 of 79 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINIMIX | 10 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498456 |
| CLINIMIX | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013932 |
| CLINIMIX | 230 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013886 |
| CLINIMIX | 310 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02046709 |
| CLINIMIX | 464 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498464 |
| CLINIMIX | 520 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013940 |
| CLINIMIX | 690 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498448 |
| CLINIMIX E | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013967 |
| CLINIMIX E | 261 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498413 |
| CLINIMIX E | 290 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02014076 |
Who else supplies COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.